Immune evasion activities of accessory proteins Vpu, Nef and Vif are conserved in acute and chronic HIV-1 infection

Virology

Volumn 482, Issue , 2015, Pages 72-78

  Mlcochova, Petra ^a   Apolonia, Luis ^b   Kluge, Silvia F ^c   Sridharan, Aishwarya ^a   Kirchhoff, Frank ^c   Malim, Michael H ^b   Sauter, Daniel ^c   Gupta, Ravindra K ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Accessory; Acute; Chronic; HIV; Nef; Vif; Vpu

Indexed keywords

CD28 ANTIGEN; CD4 ANTIGEN; INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NEF PROTEIN; VIF PROTEIN; VPU PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; NEF PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; VIF PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; VIRUS PROTEIN; VPU PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ARTICLE; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE EVASION; INNATE IMMUNITY; LIGAND BINDING; MALE; NEF GENE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; SEQUENCE ALIGNMENT; VIF GENE; VIRUS CELL INTERACTION; VIRUS INFECTIVITY; VPU GENE; CELL LINE; COMPARATIVE STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; PHYSIOLOGY; VIROLOGY; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

CELL LINE; FEMALE; HIV INFECTIONS; HIV-1; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; IMMUNE EVASION; MALE; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRAL REGULATORY AND ACCESSORY PROTEINS; VIRUS REPLICATION;

EID: 84925651414     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2015.03.015     Document Type: Article

References (37)

1. Aiken C., Trono D. Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis. J. Virol. 1995, 69:5048-5056.
2. Apolonia L., Schulz R., Curk T., Rocha P., Swanson C.M., Schaller T., Ule J., Malim M.H. Promiscuous RNA binding ensures effective encapsidation of APOBEC3 proteins by HIV-1. PLoS Pathog. 2015, 11:e1004609.
3. Baalwa J., Wang S., Parrish N.F., Decker J.M., Keele B.F., Learn G.H., Yue L., Ruzagira E., Ssemwanga D., Kamali A., Amornkul P.N., Price M.A., Kappes J.C., Karita E., Kaleebu P., Sanders E., Gilmour J., Allen S., Hunter E., Montefiori D.C., Haynes B.F., Cormier E., Hahn B.H., Shaw G.M. Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones. Virology 2013, 436:33-48.
4. Bishop K.N., Holmes R.K., Sheehy A.M., Davidson N.O., Cho S.J., Malim M.H. Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr. Biol. CB 2004, 14:1392-1396.
5. Bour S., Perrin C., Akari H., Strebel K. The human immunodeficiency virus type 1 Vpu protein inhibits NF-kappa B activation by interfering with beta TrCP-mediated degradation of Ikappa B. J. Biol. Chem. 2001, 276:15920-15928.
6. Chowers M.Y., Spina C.A., Kwoh T.J., Fitch N.J., Richman D.D., Guatelli J.C. Optimal infectivity in vitro of human immunodeficiency virus type 1 requires an intact nef gene. J. Virol. 1994, 68:2906-2914.
7. Fenton-May A.E., Dibben O., Emmerich T., Ding H., Pfafferott K., Aasa-Chapman M.M., Pellegrino P., Williams I., Cohen M.S., Gao F., Shaw G.M., Hahn B.H., Ochsenbauer C., Kappes J.C., Borrow P. Relative resistance of HIV-1 founder viruses to control by interferon-alpha. Retrovirology 2013, 10:146.
8. Fiebig E.W., Wright D.J., Rawal B.D., Garrett P.E., Schumacher R.T., Peddada L., Heldebrant C., Smith R., Conrad A., Kleinman S.H., Busch M.P. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. Aids 2003, 17:1871-1879.
9. Galao R.P., Le Tortorec A., Pickering S., Kueck T., Neil S.J. Innate sensing of HIV-1 assembly by Tetherin induces NFkappaB-dependent proinflammatory responses. Cell Host Microbe 2012, 12:633-644.
10. Garcia J.V., Miller A.D. Serine phosphorylation-independent downregulation of cell-surface CD4 by nef. Nature 1991, 350:508-511.
11. Gillick K., Pollpeter D., Phalora P., Kim E.Y., Wolinsky S.M., Malim M.H. Suppression of HIV-1 infection by APOBEC3 proteins in primary human CD4(+) T cells is associated with inhibition of processive reverse transcription as well as excessive cytidine deamination. J. Virol. 2013, 87:1508-1517.
12. Haaland R.E., Hawkins P.A., Salazar-Gonzalez J., Johnson A., Tichacek A., Karita E., Manigart O., Mulenga J., Keele B.F., Shaw G.M., Hahn B.H., Allen S.A., Derdeyn C.A., Hunter E. Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog. 2009, 5:e1000274.
13. Harris R.S., Hultquist J.F., Evans D.T. The restriction factors of human immunodeficiency virus. The Journal of Biol. Chem. 2012, 287:40875-40883.
14. Hultquist J.F., Lengyel J.A., Refsland E.W., LaRue R.S., Lackey L., Brown W.L., Harris R.S. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J. Virol. 2011, 85:11220-11234.
15. Kimura T., Nishikawa M., Ohyama A. Intracellular membrane traffic of human immunodeficiency virus type 1 envelope glycoproteins: vpu liberates Golgi-targeted gp160 from CD4-dependent retention in the endoplasmic reticulum. J. Biochem. 1994, 115:1010-1020.
16. Kirchhoff F. Immune evasion and counteraction of restriction factors by HIV-1 and other primate lentiviruses. Cell Host Microbe 2010, 8:55-67.
17. Lama J., Mangasarian A., Trono D. Cell-surface expression of CD4 reduces HIV-1 infectivity by blocking Env incorporation in a Nef- and Vpu-inhibitable manner. Curr. Biol. CB 1999, 9:622-631.
18. Moll M., Andersson S.K., Smed-Sorensen A., Sandberg J.K. Inhibition of lipid antigen presentation in dendritic cells by HIV-1 Vpu interference with CD1d recycling from endosomal compartments. Blood 2010, 116:1876-1884.
19. Neil S.J., Zang T., Bieniasz P.D. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008, 451:425-430.
20. Ochsenbauer C., Edmonds T.G., Ding H., Keele B.F., Decker J., Salazar M.G., Salazar-Gonzalez J.F., Shattock R., Haynes B.F., Shaw G.M., Hahn B.H., Kappes J.C. Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages. J. Virol. 2012, 86:2715-2728.
21. Parker Z.F., Iyer S.S., Wilen C.B., Parrish N.F., Chikere K.C., Lee F.H., Didigu C.A., Berro R., Klasse P.J., Lee B., Moore J.P., Shaw G.M., Hahn B.H., Doms R.W. Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5. J. Virol. 2013, 87:2401-2411.
22. Parrish N.F., Gao F., Li H., Giorgi E.E., Barbian H.J., Parrish E.H., Zajic L., Iyer S.S., Decker J.M., Kumar A., Hora B., Berg A., Cai F., Hopper J., Denny T.N., Ding H., Ochsenbauer C., Kappes J.C., Galimidi R.P., West A.P., Bjorkman P.J., Wilen C.B., Doms R.W., O'Brien M., Bhardwaj N., Borrow P., Haynes B.F., Muldoon M., Theiler J.P., Korber B., Shaw G.M., Hahn B.H. Phenotypic properties of transmitted founder HIV-1. Proc. Natl. Acad. Sci. USA 2013, 110:6626-6633.
23. Phalora P.K., Sherer N.M., Wolinsky S.M., Swanson C.M., Malim M.H. HIV-1 replication and APOBEC3 antiviral activity are not regulated by P bodies. J. Virol. 2012, 86:11712-11724.
24. Pickering S., Hue S., Kim E.Y., Reddy S., Wolinsky S.M., Neil S.J. Preservation of tetherin and CD4 counter-activities in circulating Vpu alleles despite extensive sequence variation within HIV-1 infected individuals. PLoS Pathog. 2014, 10:e1003895.
25. Redd A.D., Collinson-Streng A.N., Chatziandreou N., Mullis C.E., Laeyendecker O., Martens C., Ricklefs S., Kiwanuka N., Nyein P.H., Lutalo T., Grabowski M.K., Kong X., Manucci J., Sewankambo N., Wawer M.J., Gray R.H., Porcella S.F., Fauci A.S., Sagar M., Serwadda D., Quinn T.C. Previously transmitted HIV-1 strains are preferentially selected during subsequent sexual transmissions. J. Infect. Dis. 2012, 206:1433-1442.
26. Salazar-Gonzalez J.F., Salazar M.G., Keele B.F., Learn G.H., Giorgi E.E., Li H., Decker J.M., Wang S., Baalwa J., Kraus M.H., Parrish N.F., Shaw K.S., Guffey M.B., Bar K.J., Davis K.L., Ochsenbauer-Jambor C., Kappes J.C., Saag M.S., Cohen M.S., Mulenga J., Derdeyn C.A., Allen S., Hunter E., Markowitz M., Hraber P., Perelson A.S., Bhattacharya T., Haynes B.F., Korber B.T., Hahn B.H., Shaw G.M. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J. Exp. Med. 2009, 206:1273-1289.
27. Sauter D., Hotter D., Engelhart S., Giehler F., Kieser A., Kubisch C., Kirchhoff F. A rare missense variant abrogates the signaling activity of tetherin/BST-2 without affecting its effect on virus release. Retrovirology 2013, 10:85.
28. Sauter D., Hotter D., Van Driessche B., Sturzel C.M., Kluge S.F., Wildum S., Yu H., Baumann B., Wirth T., Plantier J.C., Leoz M., Hahn B.H., Van Lint C., Kirchhoff F. Differential regulation of NF-kappaB-mediated proviral and antiviral host gene expression by primate lentiviral Nef and Vpu proteins. Cell reports 2015, 10(4):586-599.
29. Sauter D., Schindler M., Specht A., Landford W.N., Munch J., Kim K.A., Votteler J., Schubert U., Bibollet-Ruche F., Keele B.F., Takehisa J., Ogando Y., Ochsenbauer C., Kappes J.C., Ayouba A., Peeters M., Learn G.H., Shaw G., Sharp P.M., Bieniasz P., Hahn B.H., Hatziioannou T., Kirchhoff F. Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe 2009, 6:409-421.
30. Schwartz O., Marechal V., Le Gall S., Lemonnier F., Heard J.M. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat. Med. 1996, 2:338-342.
31. Shah A.H., Sowrirajan B., Davis Z.B., Ward J.P., Campbell E.M., Planelles V., Barker E. Degranulation of natural killer cells following interaction with HIV-1-infected cells is hindered by downmodulation of NTB-A by Vpu. Cell Host Microbe 2010, 8:397-409.
32. Sheehy A.M., Gaddis N.C., Choi J.D., Malim M.H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002, 418:646-650.
33. Swigut T., Shohdy N., Skowronski J. Mechanism for down-regulation of CD28 by Nef. The EMBO J. 2001, 20:1593-1604.
34. Van Damme N., Goff D., Katsura C., Jorgenson R.L., Mitchell R., Johnson M.C., Stephens E.B., Guatelli J. The Interferon-Induced Protein BST-2 Restricts HIV-1 Release and Is Downregulated from the Cell Surface by the Viral Vpu Protein. Cell Host Microbe 2008, 3:245-252.
35. Wildum S., Schindler M., Munch J., Kirchhoff F. Contribution of Vpu, Env, and Nef to CD4 down-modulation and resistance of human immunodeficiency virus type 1-infected T cells to superinfection. J. Virol. 2006, 80:8047-8059.
36. Wilen C.B., Parrish N.F., Pfaff J.M., Decker J.M., Henning E.A., Haim H., Petersen J.E., Wojcechowskyj J.A., Sodroski J., Haynes B.F., Montefiori D.C., Tilton J.C., Shaw G.M., Hahn B.H., Doms R.W. Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins. J. Virol. 2011, 85:8514-8527.
37. Zheng Y.H., Irwin D., Kurosu T., Tokunaga K., Sata T., Peterlin B.M. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J. Virol. 2004, 78:6073-6076.